ACHAOGEN, INC. (NASDAQ:AKAO) Files An 8-K Financial Statements and ExhibitsItem 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit No. |
Description |
|
99.1 |
Press Release dated October 17, 2018 |
Achaogen, Inc. ExhibitEX-99.1 2 akao-ex991_6.htm EX-99.1 akao-ex991_6.htm Exhibit 99.1 Achaogen Submits Marketing Authorization Application to the European Medicines Agency for Plazomicin — MAA submission for complicated urinary tract infections (cUTI),…To view the full exhibit click here
About ACHAOGEN, INC. (NASDAQ:AKAO)
Achaogen, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterials to treat multi-drug resistant (MDR) gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant enterobacteriaceae (CRE). Plazomicin is an aminoglycoside designed to overcome clinically relevant aminoglycoside resistance mechanisms. In addition, its research and development pipeline includes two programs that specifically target Pseudomonas aeruginosa or Acinetobacter baumannii infections: a program to discover and develop small molecule inhibitors of LpxC, which is an enzyme essential for the synthesis of the outer membrane of gram-negative bacteria, and a therapeutic antibody program. Its development plan for plazomicin includes over two Phase III clinical trials.
